June 2019 - Volume 3 - Issue - Contributor Index

Author:
M, A.-P. J
Author:
M, S.-I. J
Author:
m'sadek, F.
Author:
Ma, H.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

Author:
Ma, J.
Author:
Ma, W.
Author:
Ma, W. D.

GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE: PF272

Wang, E. S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3:87, June 2019.

Author:
Ma, W. W.

CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL: PS1029

Heuser, M.; Fiedler, W.; Sekeres, M. A.; More

HemaSphere. 3:464-465, June 2019.

Author:
Ma, X.
Author:
Ma, X.-K.
Author:
Ma'koseh, M.
Author:
Maalej, S.
Author:
Maarek, A.
Author:
Maarek, O.
Author:
Macartney, C.

EXCELLENT RESPONSE TO BLINATUMOMAB IN REFRACTORY B LINEAGE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND YOUNG ADULTS AFTER DEBULKING CHEMOTHERAPY TO ACHIEVE PARTIAL REMISSION: PS948

Clesham, K.; Rao, V.; Bartram, J.; More

HemaSphere. 3:427, June 2019.

Author:
MacBeth, K.
Author:
Macdonald, D.

PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM): PF614

Tedeschi, A.; Dimopoulos, M. A.; Trotman, J.; More

HemaSphere. 3:260-261, June 2019.

Author:
Mace, S.

A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): S824

Attal, M.; Richardson, P. G.; Rajkumar, S. V.; More

HemaSphere. 3:365, June 2019.

Author:
MacEwan, D.
Author:
Machado, E.
Author:
Machado, H. B.
Author:
Machado, P.
Author:
Machalinski, B.
Author:
Machet, A.
Author:
Macheta, M.

TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: S838

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3:373, June 2019.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

Author:
Machowicz, R.

CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS - ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE: PF350

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3:126-127, June 2019.

Author:
Maciag, P.
Author:
Maciejewski, J.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

Author:
Macintyre, E.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL: S103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL: PF151

Laurent, A. P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3:28, June 2019.

MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY: PF175

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3:39-40, June 2019.

QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK: PS1312

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3:599, June 2019.

Author:
MacKinnon, R.
Author:
Mackintosh, C.
Author:
MacKnight, S.
Author:
Macon, W.
Author:
Macrì, N.
Author:
Macro, M.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PF594

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3:249-250, June 2019.

EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA: S874

Avet-Loiseau, H.; Moreau, P.; van der Velden, V. H.J.; More

HemaSphere. 3:391-392, June 2019.

Author:
Madalina, S.
Author:
Maddaloni, D.
Author:
Maddocks, K.

UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS: PF296

Duell, J.; Maddocks, K.; Barca, González E.; More

HemaSphere. 3:100, June 2019.

Author:
Madelaine, I.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Madeo, A.

MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: PF533

Martín-Izquierdo, M.; López-Cadenas, F.; del Real, Sánchez J.; More

HemaSphere. 3:219-220, June 2019.

Author:
Madkaikar, M.
Author:
Madney, Y.
Author:
Madry, K.

CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS - ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE: PF350

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3:126-127, June 2019.

Author:
Madzarova, V.
Author:
Maeda, Y.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Maekawa, T.

SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION: PS1435

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3:661-662, June 2019.

Author:
Maekawa, Y.
Author:
Maertens, J.

CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) - A MULTICENTER STUDY: PS1283

Cornely, O. A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3:587, June 2019.

Author:
Maertens, V.
Author:
Maes, K.
Author:
Maes, T.
Author:
Maestro, A.
Author:
Maffei, R.

EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY: PS1274

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3:583, June 2019.

Author:
Maffei, S.
Author:
Maffeo, B.
Author:
Maffioli, M.

RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT: PS1458

Mora, B.; Guglielmelli, P.; Rumi, E.; More

HemaSphere. 3:671, June 2019.

SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY: PS1462

Maffioli, M.; Giorgino, T.; Mora, B.; More

HemaSphere. 3:673-674, June 2019.

Show: